Bolt Biotherapeutics, Inc.Bolt Biotherapeutics, Inc.Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics, Inc.

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪28.60 M‬USD
‪−69.20 M‬USD
‪7.88 M‬USD
‪24.14 M‬
Beta (1Y)

About Bolt Biotherapeutics, Inc.

William P. Quinn
Redwood City
Employees (FY)
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Its pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.
Revenue to profit conversion
Debt level and coverage
Summarizing what the indicators are suggesting.
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of BOLT is 0.7396 USD — it has decreased by 1.40% in the past 24 hours. Watch Bolt Biotherapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Bolt Biotherapeutics, Inc. stocks are traded under the ticker BOLT.
BOLT stock has risen by 2.65% compared to the previous week, the month change is a 2.68% fall, over the last year Bolt Biotherapeutics, Inc. has showed a 45.21% decrease.
We've gathered analysts' opinions on Bolt Biotherapeutics, Inc. future price: according to them, BOLT price has a max estimate of 1.50 USD and a min estimate of 1.00 USD. Watch BOLT chart and read a more detailed Bolt Biotherapeutics, Inc. stock forecast: see what analysts think of Bolt Biotherapeutics, Inc. and suggest that you do with its stocks.
BOLT reached its all-time high on Mar 11, 2021 with the price of 43.0700 USD, and its all-time low was 0.7100 USD and was reached on Jul 10, 2024. View more price dynamics on BOLT chart.
See other stocks reaching their highest and lowest prices.
BOLT stock is 5.14% volatile and has beta coefficient of 0.86. Track Bolt Biotherapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Bolt Biotherapeutics, Inc. there?
Today Bolt Biotherapeutics, Inc. has the market capitalization of ‪28.60 M‬, it has decreased by 0.07% over the last week.
Yes, you can track Bolt Biotherapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Bolt Biotherapeutics, Inc. is going to release the next earnings report on Aug 7, 2024. Keep track of upcoming events with our Earnings Calendar.
BOLT earnings for the last quarter are −0.28 USD per share, whereas the estimation was −0.51 USD resulting in a 45.10% surprise. The estimated earnings for the next quarter are −0.46 USD per share. See more details about Bolt Biotherapeutics, Inc. earnings.
Bolt Biotherapeutics, Inc. revenue for the last quarter amounts to ‪5.27 M‬ USD, despite the estimated figure of ‪2.08 M‬ USD. In the next quarter, revenue is expected to reach ‪950.00 K‬ USD.
BOLT net income for the last quarter is ‪−10.81 M‬ USD, while the quarter before that showed ‪−17.90 M‬ USD of net income which accounts for 39.61% change. Track more Bolt Biotherapeutics, Inc. financial stats to get the full picture.
No, BOLT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jul 18, 2024, the company has 100.00 employees. See our rating of the largest employees — is Bolt Biotherapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Bolt Biotherapeutics, Inc. EBITDA is ‪−72.27 M‬ USD, and current EBITDA margin is −943.52%. See more stats in Bolt Biotherapeutics, Inc. financial statements.
Like other stocks, BOLT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Bolt Biotherapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Bolt Biotherapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Bolt Biotherapeutics, Inc. stock shows the sell signal. See more of Bolt Biotherapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.